JP2014531461A5 - - Google Patents

Download PDF

Info

Publication number
JP2014531461A5
JP2014531461A5 JP2014533645A JP2014533645A JP2014531461A5 JP 2014531461 A5 JP2014531461 A5 JP 2014531461A5 JP 2014533645 A JP2014533645 A JP 2014533645A JP 2014533645 A JP2014533645 A JP 2014533645A JP 2014531461 A5 JP2014531461 A5 JP 2014531461A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
inhibitor
active agent
combination
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014533645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531461A (ja
JP6224597B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/057085 external-priority patent/WO2013049045A1/en
Publication of JP2014531461A publication Critical patent/JP2014531461A/ja
Publication of JP2014531461A5 publication Critical patent/JP2014531461A5/ja
Application granted granted Critical
Publication of JP6224597B2 publication Critical patent/JP6224597B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014533645A 2011-09-27 2012-09-25 グリオーマを処置するための組成物及び方法 Expired - Fee Related JP6224597B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539779P 2011-09-27 2011-09-27
US61/539,779 2011-09-27
PCT/US2012/057085 WO2013049045A1 (en) 2011-09-27 2012-09-25 Compositions and methods of treating gliomas

Publications (3)

Publication Number Publication Date
JP2014531461A JP2014531461A (ja) 2014-11-27
JP2014531461A5 true JP2014531461A5 (enExample) 2015-12-03
JP6224597B2 JP6224597B2 (ja) 2017-11-01

Family

ID=47996335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533645A Expired - Fee Related JP6224597B2 (ja) 2011-09-27 2012-09-25 グリオーマを処置するための組成物及び方法

Country Status (5)

Country Link
US (1) US9757424B2 (enExample)
EP (1) EP2760473A1 (enExample)
JP (1) JP6224597B2 (enExample)
CN (1) CN103930132A (enExample)
WO (1) WO2013049045A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
WO2014023329A1 (en) * 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
TWI621434B (zh) * 2014-10-24 2018-04-21 朗齊生物醫學股份有限公司 千憂解藥物應用於癌症治療
KR101773244B1 (ko) * 2015-02-27 2017-09-01 이화여자대학교 산학협력단 암로디핀을 포함하는 뇌종양 예방 또는 치료용 약학적 조성물
CA2992674A1 (en) * 2015-07-31 2017-02-09 Inflectis Bioscience Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent
CN107088194A (zh) * 2016-02-17 2017-08-25 深圳市坤健创新药物研究院 药物氨氯地平的新用途
TW201739453A (zh) * 2016-04-29 2017-11-16 奧托德里克有限公司 使用ace抑制劑、arb或西里柯斯比(celecoxib)及奧美沙坦(olmesartan)之用於治療癌症的方法
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
KR102005887B1 (ko) * 2016-12-09 2019-07-31 서울대학교산학협력단 뇌종양의 예방 또는 치료용 약학 조성물
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
CN111773377B (zh) * 2019-04-04 2023-03-14 中南大学 阿尼芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment
KR102920763B1 (ko) * 2019-10-04 2026-02-02 의료법인 성광의료재단 옥시토신 수용체 억제제를 포함하는 조성물 및 이의 용도
CN110876800B (zh) * 2019-11-18 2023-06-27 中南大学 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN110960533A (zh) * 2019-12-31 2020-04-07 苏州青雅启瑞生物科技有限公司 马尼地平联用替莫唑胺及其药物组合在制备用于治疗脑胶质瘤的药物中的应用
US12076315B2 (en) 2020-03-20 2024-09-03 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease
CN111803497A (zh) * 2020-09-02 2020-10-23 中国科学院昆明动物研究所 乐卡地平类药物在制备治疗人神经胶质瘤药物中的用途
JP7837561B2 (ja) * 2020-10-28 2026-03-31 国立大学法人東海国立大学機構 悪性中皮腫の治療剤および悪性中皮腫患者の選択方法
JP7804698B2 (ja) * 2021-05-07 2026-01-22 イーライ リリー アンド カンパニー ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の味マスキングされた組成物、及びそれを含む経口崩壊錠剤
KR102893290B1 (ko) * 2021-12-17 2025-12-01 숙명여자대학교산학협력단 뇌종양 치료를 위한 글리세오플빈 병용요법
WO2023113538A1 (ko) * 2021-12-17 2023-06-22 숙명여자대학교산학협력단 뇌종양 치료를 위한 글리세오플빈 병용요법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078147A2 (en) * 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
US20060009506A1 (en) 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
EP1851197A2 (en) * 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
DK1940461T3 (da) * 2005-11-02 2014-03-31 Univ Duke Samtidig kemoterapi og immunterapi
US20070141066A1 (en) * 2005-12-16 2007-06-21 Genentech, Inc. Method for Diagnosing, Prognosing and Treating Glioma
TWI494134B (zh) * 2006-06-20 2015-08-01 Siegfried Generics Int Ag 含有坎地沙坦酯的組成物、錠劑和顆粒及該錠劑的製造方法
ES2780193T3 (es) * 2006-07-12 2020-08-24 Univ Tennessee Res Found Compuesto para tratar el cáncer de mama y afecciones dependientes de la progestina
EP1958637A1 (en) * 2007-02-14 2008-08-20 Revotar Biopharmaceuticals AG Pharmaceutical composition for the treatment of IL-8 mediated diseases
JP2010518147A (ja) * 2007-02-16 2010-05-27 ノバルティス アーゲー 有機化合物の使用
TWI473610B (zh) 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物

Similar Documents

Publication Publication Date Title
JP6224597B2 (ja) グリオーマを処置するための組成物及び方法
TWI898227B (zh) 匹莫苯坦（ｐｉｍｏｂｅｎｄａｎ）用於在患有由二尖瓣疾病所致之無症狀心臟衰竭之患者中減小心臟大小及/或延遲臨床症狀之發作的用途
JP2010511621A5 (enExample)
RU2014111474A (ru) Способы лечения сердечно-сосудистых нарушений
JP2014515402A5 (enExample)
JP2012525323A5 (enExample)
JP2020506180A5 (enExample)
FR19C1030I1 (fr) Systeme d'administration de medicament pour administrer des substances pharmaceutiquement actives pauvrement hydrosolubles
CA2439920A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
RU2019126749A (ru) Композиции для лечения гипертензии
AU2002336267A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
CN115721635A (zh) 丙戊酸的医疗用途
CN101300030A (zh) 血管紧张素ⅱ受体阻滞剂、钙通道阻滞剂和另一活性物质的组合产品
CN1187050C (zh) 内皮素拮抗剂和血管紧张肽原酶－血管紧张肽系统抑制剂的联合体系
RU2001132073A (ru) Фармацевтическая композиция для предотвращения, лечения или ингибирования развития простой ретинопатии и препролиферирующей ретинопатии
AU2005294318A1 (en) Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
AU2002363089B2 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a COX-2 inhibitor and a taxol
US20180036281A1 (en) Pharmaceutical for prophylaxis or treatment of hypertension
Whitworth Emerging drugs in the management of hypertension
JP2018521077A5 (enExample)
US20040116510A1 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
RU2012102518A (ru) Лекарственное средство для лечения гипертензии или повышенного кровяного давления
CN108778334A (zh) 用于治疗肾脏疾病的药物
CN1589154A (zh) 含有血管紧张肽ii受体拮抗剂的药用组合物
JP2010031006A5 (enExample)